Home › Trial NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
- Trial IDNCT06970847
- StatusActive Not Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorClarity Pharmaceuticals Ltd
- Enrollment220
- Start date2025-05-16
- ConditionsProstate Cancer · Prostate Cancer Patients With Detectable PSA Following Prostatectomy · Prostate Cancer Recurrent · Prostate Cancer Patients Who Have Brachytherapy Seed Implant · Prostate Cancer Patients Treated by Radiotherapy · Cryotherapy
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.